VC
Value Add VC
โšกHomePulseโšกHelpful Apps๐Ÿ“Blog
โ† Value Add PulseFUNDING$135M Series A

Chamath Palihapitiya Raises $135M for AI Coding Startup 8090 Labs, Returns as CEO

Chamath Palihapitiya's 8090 Labs raised a $135 million Series A led by Salesforce Ventures, with Palihapitiya taking the CEO role -- his first full-time operating job since leaving Facebook -- to scale Software Factory, an AI coding platform built for regulated industries including healthcare, insurance, aerospace and government, TechCrunch reported June 29.

$135M Series A
Round Size
Salesforce Ventures
Lead Investor
WndrCo, Craft Ventures, The Production Board, Launch
Other Investors
January 2024
Founded
Healthcare, insurance, life sciences, aerospace, energy, manufacturing, government
Target Industries
TC
Trace Cohen
Early-stage VC & angel ยท Founder, New York Venture Partners
June 29, 2026
2 min read
ShareXLinkedInEmail
KEY TAKEAWAYS FOR VCs & FOUNDERS
1

A prominent VC personally stepping back into an operating CEO role is a notable reversal of the usual investor-to-founder direction, and a bet that AI coding for regulated industries needs hands-on execution, not just capital

2

Salesforce Ventures leading, rather than a pure financial VC, signals enterprise software incumbents see AI-generated code for regulated markets as strategically adjacent to their own platforms

3

Targeting audit trails and compliance controls -- not just raw code generation -- is a meaningfully different pitch than most consumer-facing AI coding tools competing purely on speed

4

Angel investors including Palo Alto Networks CEO Nikesh Arora and Quora's Adam D'Angelo show cross-industry executive conviction in the regulated-AI-coding niche specifically

TC
The VC Read ยท Trace's TakeTrace Cohen

A well-known VC stepping back into a full-time operating CEO role, for the first time since Facebook, is a bigger signal of conviction than the $135M itself -- Palihapitiya could have stayed purely as an investor and let someone else run this, and choosing not to tells you he thinks the regulated-industry AI-coding niche specifically needs founder-level focus to win. Salesforce Ventures leading rather than a pure financial VC is the detail worth watching: enterprise incumbents increasingly see compliance-aware AI coding as adjacent to their own platforms, not just a startup category to observe from a distance. The competitive field here is genuinely crowded -- Cursor, Claude Code, Copilot and now Z.ai's ZCode are all fighting for developer attention -- so 8090's bet has to be that audit trails and governance are a real wedge, not just a marketing angle, against faster-moving general-purpose tools. For founders in regulated-industry AI tooling, this raise and Palihapitiya's personal commitment validate the category at a level most startups in this space can't match. Watch how fast Software Factory converts this raise into named customer wins in healthcare, insurance or government -- that's the real test of whether the compliance-first pitch holds up.

๐Ÿ’ฐ VC Fundraises 2026 โ†’๐Ÿข Enterprise AI Adoption โ†’

Chamath Palihapitiya's 8090 Labs raised a $135 million Series A led by Salesforce Ventures, with participation from WndrCo, Craft Ventures, The Production Board and Launch, TechCrunch reported June 29, 2026. As part of the round, Palihapitiya is taking over as CEO -- his first full-time operating role since leaving Facebook, having spent the intervening years running his venture firm Social Capital and co-hosting the All-In podcast.

8090 Labs, which Palihapitiya founded in January 2024, builds Software Factory, an AI coding platform designed specifically for corporate engineering teams operating in regulated industries -- healthcare, insurance, life sciences, aerospace, energy, manufacturing, financial services and the US government. The platform's core pitch is producing production-ready code while preserving the audit trails, compliance controls and other governance requirements that regulated enterprises need and that most general-purpose AI coding tools weren't built to handle.

Salesforce Ventures leading the round, rather than a pure financial venture fund, is a notable strategic signal: enterprise software incumbents increasingly see AI-generated code for regulated, compliance-heavy markets as adjacent to their own core platforms, rather than a purely disruptive threat to be watched from a distance. The round's angel investor list reinforces that cross-industry executive interest -- Palo Alto Networks CEO Nikesh Arora and Quora CEO Adam D'Angelo both participated personally, alongside other named individual investors.

โ€œPalihapitiya taking the CEO seat himself, rather than continuing purely as an investor or board member, is the more unusual element of the story.โ€

Palihapitiya taking the CEO seat himself, rather than continuing purely as an investor or board member, is the more unusual element of the story. Prominent venture investors stepping back into full-time operating roles at their own portfolio companies is rare, and doing so specifically to run an AI coding company targeting regulated industries -- rather than a higher-profile consumer AI product -- suggests genuine conviction that this specific, less glamorous niche requires focused, hands-on execution to win.

The competitive backdrop is already crowded and fast-moving: this issue separately covers Z.ai's ZCode launch challenging Cursor, Claude Code and GitHub Copilot, and Gartner's Enterprise AI Coding Agents category already tracking an estimated $9.8-11 billion annualized market. 8090 Labs' bet is that the specific sub-segment of regulated-industry compliance requirements is underserved by the broader coding-agent market, which has mostly optimized for developer speed and general-purpose flexibility rather than audit-trail preservation and compliance-grade governance.

For founders building AI tools for regulated industries, 8090 Labs' raise and Palihapitiya's operating commitment validate that compliance-aware AI coding is a distinct, fundable category worth building for specifically, rather than a feature to bolt onto a general-purpose product. For investors, a well-known VC returning to full-time operating work at his own portfolio company is worth watching as a signal of how seriously experienced investors now rate the compliance-and-governance layer of enterprise AI coding.

What to watch: how quickly Palihapitiya's operating focus translates into customer wins across 8090 Labs' target regulated industries, whether Software Factory's compliance-first positioning holds up against faster-moving general-purpose coding agents adding their own governance features, and whether other prominent VCs follow Palihapitiya's example of stepping back into operating roles at portfolio companies they believe in enough to run personally.

ShareXLinkedInEmail
More onSalesforce โ†’

Originally reported by TechCrunch. Analysis and editorial commentary by Value Add Pulse.

โ† Back to Pulse

Read Next

FUNDINGNew firm targets AI infra, energy, deep tech

Ashton Kutcher Leaves Sound Ventures to Launch a New Firm With Morgan Beller

Ashton Kutcher is departing Sound Ventures, the firm he co-founded 11 years ago with Guy Oseary, to launch a new early-stage firm with Morgan Beller -- a former Andreessen Horowitz partner and NFX general partner who also co-led Meta's Libra cryptocurrency project -- targeting AI infrastructure, energy and deep tech, TechCrunch reported July 1. The new firm's name and fund size have not yet been disclosed, and Kutcher will remain an adviser to Sound Ventures while Oseary and GP Effie Epstein advise the new firm.

FUNDING$54.2M Series B

Nobel Laureate's Qolab Raises $54.2M Series B to Scale Superconducting Quantum Chips

Qolab, a Santa Barbara superconducting-quantum-processor startup co-founded by 2025 Nobel physics laureate John Martinis, closed a $54.2 million Series B led by UC Investments on July 2, with WARF, Octave Ventures and Phoenix Venture Partners also participating, to fund semiconductor fabrication partnerships and manufacturing scale-up toward fault-tolerant quantum computing.

FUNDING$180M Series B

Celea Therapeutics Raises $180M Series B for Pulmonary Fibrosis Drug

Celea Therapeutics, a clinical-stage biotech spun out of PureTech developing deupirfenidone for idiopathic pulmonary fibrosis, announced a $180 million Series B on July 2, led by RA Capital and Leaps by Bayer, with PureTech and additional unnamed health-focused and sovereign funds participating, per weekly funding roundups covering the deal.

@Trace_Cohenยทt@nyvp.com